PolyPeptide Group (Switzerland) Today
| PPGN Stock | CHF 25.65 0.85 3.21% |
Performance0 of 100
| Odds Of DistressLess than 10
|
PolyPeptide Group is selling for under 25.65 as of the 1st of February 2025; that is 3.21 percent decrease since the beginning of the trading day. The stock's lowest day price was 25.65. PolyPeptide Group has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. The company was founded in 1952 and is headquartered in Zug, Switzerland. POLYPEPTIDE is traded on Switzerland Exchange in Switzerland. The company has 33.12 M outstanding shares. More on PolyPeptide Group AG
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
PolyPeptide Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. PolyPeptide Group's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding PolyPeptide Group or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
PolyPeptide Group AG (PPGN) is traded on SIX Swiss Exchange in Switzerland and employs 1,156 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 823.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PolyPeptide Group's market, we take the total number of its shares issued and multiply it by PolyPeptide Group's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. PolyPeptide Group operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 33.12 M outstanding shares.
PolyPeptide Group AG has accumulated about 136.3 M in cash with 57.35 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67.
Check PolyPeptide Group Probability Of Bankruptcy
Ownership AllocationPolyPeptide Group owns a total of 33.12 Million outstanding shares. PolyPeptide Group has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PolyPeptide Ownership Details
PolyPeptide Group Risk Profiles
Although PolyPeptide Group's alpha and beta are two of the key measurements used to evaluate PolyPeptide Group's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.04 | |||
| Standard Deviation | 2.82 | |||
| Variance | 7.94 | |||
| Risk Adjusted Performance | (0.02) |
PolyPeptide Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in PolyPeptide Group without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
PolyPeptide Group Corporate Management
Elected by the shareholders, the PolyPeptide Group's board of directors comprises two types of representatives: PolyPeptide Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PolyPeptide. The board's role is to monitor PolyPeptide Group's management team and ensure that shareholders' interests are well served. PolyPeptide Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PolyPeptide Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Miller | Chief Officer | Profile | |
| Daniel Lasanow | Director Operations | Profile | |
| Michael Staheli | Head Communications | Profile | |
| Jan Christensen | Ex Officer | Profile | |
| Neil Thompson | Director Marketing | Profile | |
| Monika Casanova | Chief Officer | Profile | |
| Raymond Vre | Chief Officer | Profile |
Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.